The Filings Report

Astera Labs

ALABNasdaqCIK 1736297Technology / Semiconductorsfiscal year ends December14 quarters since 2023

Revenue, Q2 FY2026
$392M
+104.5% on Q2 FY2025
Net income
$153M
+198.9% on Q2 FY2025
Free cash flow
$67M
−49.6% on Q2 FY2025
Diluted EPS
$0.83
+186.2% on Q2 FY2025
Revenue, TTM
$1.2B
trailing four quarters
Net margin, TTM
30.7%
net income $369M
Free cash flow, TTM
$277M
$336M less $59M capex
Cash and equivalents
$111M
long-term debt —, Jun 30, 2026
Shares, 12-month change
+4.4%
173M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$44.9B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Astera Labs reported revenue of $392M, +104.5% on Q2 FY2025, and net income of $153M (+198.9%). Operating margin was 22.7%. Free cash flow, operating cash flow less capital expenditures, was $67M ($88M less $20M). Diluted earnings per share were $0.83.

The last 14 quarters

Q1 FY2023 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$200M$0$200M$400MQ1'23, Revenue: $18MQ1'23, Net income: −$17MQ1'23Q2'23, Revenue: $11MQ2'23, Net income: −$20MQ2'23Q3'23, Revenue: $37MQ3'23, Net income: −$3MQ3'23Q4'23, Revenue: $51MQ4'23, Net income: $14MQ4'23Q1'24, Revenue: $65MQ1'24Q2'24, Revenue: $77MQ2'24, Net income: −$8MQ2'24Q3'24, Revenue: $113MQ3'24, Net income: −$8MQ3'24Q4'24, Revenue: $141MQ4'24, Net income: $25MQ4'24Q1'25, Revenue: $159MQ1'25, Net income: $32MQ1'25Q2'25, Revenue: $192MQ2'25, Net income: $51MQ2'25Q3'25, Revenue: $231MQ3'25, Net income: $91MQ3'25Q4'25, Revenue: $271MQ4'25, Net income: $45MQ4'25Q1'26, Revenue: $308MQ1'26, Net income: $80MQ1'26Q2'26, Revenue: $392MQ2'26, Net income: $153MQ2'26−$200M$0$200M$400MQ1'23, Revenue: $18MQ1'23, Net income: −$17MQ2'23, Revenue: $11MQ2'23, Net income: −$20MQ2'23Q3'23, Revenue: $37MQ3'23, Net income: −$3MQ4'23, Revenue: $51MQ4'23, Net income: $14MQ4'23Q1'24, Revenue: $65MQ2'24, Revenue: $77MQ2'24, Net income: −$8MQ2'24Q3'24, Revenue: $113MQ3'24, Net income: −$8MQ4'24, Revenue: $141MQ4'24, Net income: $25MQ4'24Q1'25, Revenue: $159MQ1'25, Net income: $32MQ2'25, Revenue: $192MQ2'25, Net income: $51MQ2'25Q3'25, Revenue: $231MQ3'25, Net income: $91MQ4'25, Revenue: $271MQ4'25, Net income: $45MQ4'25Q1'26, Revenue: $308MQ1'26, Net income: $80MQ2'26, Revenue: $392MQ2'26, Net income: $153MQ2'26

Net income losses drawn in red.

Free cash flow
−$50M$0$50M$100M$150MQ1'23, Free cash flow: −$4MQ1'23Q2'23, Free cash flow: −$24MQ2'23Q3'23, Free cash flow: −$1MQ3'23Q4'23, Free cash flow: $13MQ4'23Q1'24, Free cash flow: $228KQ1'24Q2'24, Free cash flow: $31MQ2'24Q3'24, Free cash flow: $47MQ3'24Q4'24, Free cash flow: $24MQ4'24Q1'25, Free cash flow: $6MQ1'25Q2'25, Free cash flow: $133MQ2'25Q3'25, Free cash flow: $66MQ3'25Q4'25, Free cash flow: $77MQ4'25Q1'26, Free cash flow: $67MQ1'26Q2'26, Free cash flow: $67MQ2'26−$50M$0$50M$100M$150MQ1'23, Free cash flow: −$4MQ2'23, Free cash flow: −$24MQ2'23Q3'23, Free cash flow: −$1MQ4'23, Free cash flow: $13MQ4'23Q1'24, Free cash flow: $228KQ2'24, Free cash flow: $31MQ2'24Q3'24, Free cash flow: $47MQ4'24, Free cash flow: $24MQ4'24Q1'25, Free cash flow: $6MQ2'25, Free cash flow: $133MQ2'25Q3'25, Free cash flow: $66MQ4'25, Free cash flow: $77MQ4'25Q1'26, Free cash flow: $67MQ2'26, Free cash flow: $67MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600M$800MQ1'23Q2'23Q3'23Q4'23, Cash and equivalents: $45MQ4'23Q1'24, Cash and equivalents: $696MQ1'24Q2'24, Cash and equivalents: $421MQ2'24Q3'24, Cash and equivalents: $126MQ3'24Q4'24, Cash and equivalents: $80MQ4'24Q1'25, Cash and equivalents: $86MQ1'25Q2'25, Cash and equivalents: $162MQ2'25Q3'25, Cash and equivalents: $140MQ3'25Q4'25, Cash and equivalents: $168MQ4'25Q1'26, Cash and equivalents: $148MQ1'26Q2'26, Cash and equivalents: $111MQ2'26$0$200M$400M$600M$800MQ2'23Q4'23, Cash and equivalents: $45MQ4'23Q1'24, Cash and equivalents: $696MQ2'24, Cash and equivalents: $421MQ2'24Q3'24, Cash and equivalents: $126MQ4'24, Cash and equivalents: $80MQ4'24Q1'25, Cash and equivalents: $86MQ2'25, Cash and equivalents: $162MQ2'25Q3'25, Cash and equivalents: $140MQ4'25, Cash and equivalents: $168MQ4'25Q1'26, Cash and equivalents: $148MQ2'26, Cash and equivalents: $111MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Astera Labs income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue392308271231192159141113+104.5%
Cost of revenue10573665546403725+126.1%
Gross profit28823520417614611910488+97.6%
Research and development136126947967655751+103.7%
Selling, general and administrative3626242220222523+76.2%
Operating income8962675540110(9)+124.4%
Other income (expense)—————————
Pretax income1037379675122112+103.0%
Income tax(50)(7)34(24)(1)—(14)10−8875.5%
Net income153804591513225(8)+198.9%
Diluted EPS ($)0.830.44—0.500.290.18—(0.05)+186.2%
Diluted shares (millions)183181—181178178—157—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Astera Labs balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents1111481681401628680126−31.3%
Short-term investments1,1421,0361,021994903838835761+26.4%
Total current assets1,6521,4131,3621,2901,1811,0761,013946+39.9%
Total assets1,9321,6591,5321,4011,2711,1221,055983+51.9%
Total current liabilities164125133101106778788+54.4%
Long-term debt—————————
Total liabilities206165168129136809093+51.7%
Stockholders’ equity1,7261,4941,3641,2721,1361,042965890+51.9%
Shares outstanding (millions)173171170169166165162159—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Astera Labs cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow88759578135114064−35.2%
Capital expenditures2081912251517+911.8%
Free cash flow (CFO − capex)6767776613362447−49.6%
Depreciation and amortization443211withheldwithheld+178.6%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 20, 2026.

Income statement

Astera Labs income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed May 8, 2024FY2022ended Dec 31, 2022filed May 8, 2024
Revenue85339611680
Cost of revenue207943621
Gross profit6453038059
Research and development3042017374
Selling, general and administrative88941621
Operating income173(116)(29)(60)
Other income (expense)————
Pretax income218(82)(23)(58)
Income tax(1)231
Net income219(83)(26)(58)
Diluted EPS ($)1.22(0.64)(0.71)(1.71)
Diluted shares (millions)1801313734

Balance sheet

Astera Labs balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed May 8, 2024FY2022ended Dec 31, 2022filed May 8, 2024
Cash and equivalents1688045—
Short-term investments1,021835104—
Total current assets1,3621,013186—
Total assets1,5321,055196—
Total current liabilities1338735—
Long-term debt————
Total liabilities1689039—
Stockholders’ equity1,364965(98)(85)
Shares outstanding (millions)170162——

Cash flow statement

Astera Labs cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed May 8, 2024FY2022ended Dec 31, 2022filed May 8, 2024
Operating cash flow319137(13)(36)
Capital expenditures383434
Free cash flow (CFO − capex)282102(15)(40)
Depreciation and amortization732—
Share repurchases0100
Dividends paid————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$127M
102 sales by 5 insiders; officers and directors $127M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$784M
504 sales by 8 insiders; officers and directors $784M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 7, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-13,505$376.06$1M47,019Oct 9, 2026
Oct 7, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect8,333$376.06$3M286,400Oct 9, 2026
Oct 7, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect661$376.06$249K2,648Oct 9, 2026
Oct 1, 2026Barratt Craig HDirectoraward68$311.57$21K6,893Oct 9, 2026
Oct 1, 2026Hurlston Michael E.Directoraward72$311.57$22K92,554Oct 9, 2026
Oct 1, 2026Dyckerhoff Stefan ADirectoraward68$311.57$21K50,524Oct 9, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1273$273.64$75K53,688Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect650$273.64$178K302,416Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect52$273.64$14K3,918Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-12,275$274.79$625K51,413Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect5,409$274.79$1M297,007Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect429$274.79$118K3,489Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1785$275.53$216K50,628Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect1,867$275.53$514K295,140Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect148$275.53$41K3,341Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1172$276.75$48K50,456Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect407$276.75$113K294,733Sep 3, 2026
Sep 2, 2026Dyckerhoff Stefan ADirectoropen-market sale10b5-1indirect32$276.75$9K3,309Sep 3, 2026
Sep 1, 2026Alba ManuelDirectoropen-market sale10b5-1indirect2,575$277.32$714K1MSep 3, 2026
Sep 1, 2026Alba ManuelDirectoropen-market sale10b5-1indirect20,991$278.33$6M1MSep 3, 2026
Sep 1, 2026Alba ManuelDirectoropen-market sale10b5-1indirect37,176$279.28$10M1MSep 3, 2026
Sep 1, 2026Alba ManuelDirectoropen-market sale10b5-1indirect59,379$280.04$17M1MSep 3, 2026
Sep 1, 2026Alba ManuelDirectoropen-market sale10b5-1indirect12,882$281.16$4M1MSep 3, 2026
Sep 1, 2026Alba ManuelDirectoropen-market sale10b5-1indirect5,870$282.13$2M1MSep 3, 2026
Sep 1, 2026Alba ManuelDirectoropen-market sale10b5-1indirect3,954$283.19$1M1MSep 3, 2026

Full insider history for Astera Labs, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Astera Labs, Inc., CIK 1736297 on EDGAR
Extract generated
August 28, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2024
Repaired
3 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2023, net income FY2024, income tax FY2025
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): not filed
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated August 28, 2026.

JSON file
/data/financials/ALAB.json